T-CURX GmbH

📍 Würzburg, Germany🗓 Founded 2017👥 8 employees💰 Last funded Dec 2022
Biotechnology Research🌐 t-curx.com
Website LinkedIn
T-CURX is a Biotech company, spun-out from the University Clinics Würzburg, Germany, developing first- and best-in-class personalized immunotherapies on the basis of CAR-T cells. CAR-T cells are a transformative, one-shot, chemotherapy-free targeted and personalized cancer treatment. T-CURX has exclusive licenses for proprietary technologies and CAR-T product opportunities developed in the laboratory of Prof. M. Hudecek, Würzburg, Germany one of the leading European clinical CAR-T cell laboratories. T-CURX leverages several cutting-edge CAR-T engineering technologies, including virus-free transposon based genetic engineering and a highly flexible and modular CAR format. This provides unparalleled flexibility, efficacy, safety, but also scalability for developing CAR-T cells at significantly lower costs than conventional lentivirus-based CAR-T cell manufacturing.
2
Total investors
0
Early stage
2
Mid stage
0
Late stage
2017
Founded

Investors

2 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
Germany
2
Frequently asked questions
Who invested in T-CURX GmbH?
T-CURX GmbH has 2 investors on record on gritt.io, 2 mid-stage.
When did T-CURX GmbH last raise funding?
The most recent investment in T-CURX GmbH recorded on gritt.io was in December 2022.
When was T-CURX GmbH founded?
T-CURX GmbH was founded in 2017.
What industry is T-CURX GmbH in?
T-CURX GmbH operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is T-CURX GmbH based?
T-CURX GmbH is headquartered in Würzburg, Germany.